Funding for this research was provided by:
National Institutes of Health (1R21NS106078-01A1, 1R01DC016519-01, 5R21NS093993-02)
Innovative Medicines Initiative (PD-MitoQUANT grant No 821522, IMPRiND grant No 116060)
EU Joint Programme – Neurodegenerative Disease Research
Fondation Simone et Cino Del Duca
Fondation Bettencourt Schueller (N/A)
Fondation pour la Recherche Médicale (N/A)
Centre National de la Recherche Scientifique (N/A)
Peter C. and Emajean Cook Foundation (N/A)
Text and Data Mining valid from 2019-12-01
Received: 22 November 2019
Accepted: 25 November 2019
First Online: 30 December 2019
: The housing of the animals and all procedures were in accordance with the Guide for the care and Use of Laboratory Animals (US National Institutes of Health) and were approved by the Van Andel Research institute’s IACUC (AUP 14–01-001 and AUP 16–12-033).
: P.B. has received commercial support as a consultant from Axial Biotherapeutics, CuraSen, Fujifilm-Cellular Dynamics International, IOS Press Partners, LifeSci Capital LLC, Lundbeck A/S and Living Cell Technologies LTD. He has received commercial support for grants/research from Lundbeck A/S and Roche. He has ownership interests in Acousort AB and Axial Biotherapeutics and is on the steering committee of the NILO-PD trial.The authors declare no additional competing financial interests.